Evolent HealthEVH +2.19%60 3-Year ROIIC % is -28.66 as of Dec. 2025. GuruFocus rates EVH with a GF Score™ of 60/100 and a GF Value™ of $11.22 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 620 Healthcare Providers & Services companies, Evolent Health ranks worse than 79.84% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Evolent Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -28.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Evolent Health's 3-Year ROIIC % or its related term are showing as below:
EVH's 3-Year ROIIC % is ranked worse than 79.84% of 620
companies
in the Healthcare Providers & Services industry
Industry Median: 3.28
vs EVH: -28.66
Evolent Health (NYSE:EVH) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Evolent Health 3-Year ROIIC % Related Terms
Evolent Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Evolent Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Evolent Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Evolent Health's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Evolent Health (EVH) has a 3-Year ROIIC % of -28.66 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #495 out of 620 companies in the Healthcare Providers & Services industry, placing it in the top 79.8%.
Is Evolent Health's 3-Year ROIIC % too high?
Evolent Health's current 3-Year ROIIC % is -28.66. Based on the distribution chart, Evolent Health ranks #495 out of 620 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's 3-Year ROIIC % compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #495 out of 620 companies for 3-Year ROIIC %. This places Evolent Health in the lower half of its industry. The industry median 3-Year ROIIC % is 3.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.28, based on 620 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current 3-Year ROIIC % is -28.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.22, compared to a current price of $5.60 — trading 50.1% below its estimated fair value. The current 3-Year ROIIC % is -28.66. Evolent Health's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Evolent Health (EVH), the current 3-Year ROIIC % is -28.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $5.60 is trading 50.1% below its estimated GF Value™ of $11.22.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
3-Year ROIIC %: -28.66
GF Value™: $11.22 vs. price of $5.60 (50.1% below fair value)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
60GF Score
Get the complete analysis for EVH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
